FDA Class I thyroid recall covers 1,955 bottles: UAE pharmacies should check Lot 504950

Vitruvias Therapeutics has had a thyroid medicine recall elevated to the U.S. Food and Drug Administration (FDA) Class I level, covering 1,955 bottles of Thyroid Tablets, USP 30 mg in Lot 504950, a batch that UAE pharmacies should now screen for in imported stock and patient-held supplies.

The recall matters most to pharmacy COOs, insurers and medical directors because thyroid hormone has a narrow dose tolerance. A superpotent product can push a stable hypothyroid patient into iatrogenic hyperthyroidism. In Dubai, the practical question is whether any private pharmacy, clinic pharmacy or traveller-held medicine falls outside the usual local supply chain. The Dubai Health Authority (DHA) regulates Dubai facilities, the Department of Health Abu Dhabi (DOH) regulates Abu Dhabi and Al Ain, and the Ministry of Health and Prevention (MOHAP) remains relevant for the northern emirates alongside federal medicines oversight by the Emirates Drug Establishment (EDE).

What was recalled

The FDA-published company notice says Vitruvias initiated the recall on 21 August 2026, and the FDA published it on 24 August 2026. The FDA notice identifies the product as Thyroid Tablets, USP 30 mg, NDC 69680-166-00, Lot 504950, expiring 30 September 2026. Vitruvias reported 3,655 units released and 1,955 units sold, with U.S. distribution to direct accounts between 31 January 2025 and 30 September 2025.

Gulf Coast News and Weather, via News4JAX, reported on 24 September 2026 that the recall had been classified at the FDA’s highest risk level. Its report said the FDA centre classification date was 22 September 2026. News4JAX also reported that the affected 30 mg tablet is labelled as containing 19 micrograms of levothyroxine (T4) and 4.5 micrograms of liothyronine (T3).

“Patients who are currently taking Thyroid, USP from Lot 504950, which is being recalled, should not discontinue use without contacting their healthcare provider.” — Vitruvias Therapeutics notice published by the FDA

Dubai pharmacy checks

Dubai operators should treat this as a dispensing-record audit and patient counselling issue. DHA’s Drug Control section says it oversees medication governance in Dubai according to classifications approved by EDE. For a thyroid recall, the first operational step is to search pharmacy systems for the product name, NDC, manufacturer and lot number. The second is to ask patients using imported desiccated thyroid products to bring original packaging, because UAE-dispensed levothyroxine brands may differ from U.S. natural thyroid preparations.

• Check Lot 504950, NDC 69680-166-00 and expiry 30 September 2026.
• Flag higher-risk patients: elderly patients, pregnant women and infants, the same groups named in the FDA notice.
• Record symptoms such as rapid heart rate, chest pain, hypertension, heat intolerance and weight loss in the patient file.
• Escalate suspected adverse reactions through the relevant UAE channel: DHA in Dubai, DOH Abu Dhabi in Abu Dhabi and Al Ain, and MOHAP or EDE routes for northern emirates and federal product issues.

For CFOs and insurers, the cost exposure is small per prescription and larger in follow-up utilisation. Historical MOHAP price lists put Eltroxin 100 mcg, 100 tablets at AED 22.50 in a 2016 public price list and Euthyrox 100 mcg, 100 tablets at AED 29.50 in a 2013 public price list. Those are old regulated-price references, so reimbursement teams should verify current products and prices in the EDE registered medical product directory before changing formularies or patient co-pay guidance.

What UAE clinics should do next

Clinics should avoid substituting thyroid therapy without a prescriber review. The recalled product is a porcine-derived thyroid preparation containing T4 and T3, while many UAE patients receive synthetic levothyroxine. Switching between those therapies can change dose exposure, laboratory interpretation and symptoms within weeks. Medical directors should require a documented medicine reconciliation for any patient who presents with U.S.-sourced thyroid tablets or unexplained hyperthyroid symptoms after travel.

Insurers such as Daman, Thiqa and Sukoon should expect queries about replacement prescriptions, thyroid-stimulating hormone testing and endocrinology follow-up. Coverage decisions will depend on the member’s policy, network and diagnosis coding, so call-centre scripts should direct patients to their network pharmacy and treating physician rather than advising abrupt discontinuation.

The next local signal would be a UAE circular naming the product, lot or importer. Until then, pharmacy leaders should document negative stock checks and keep patient advice consistent with the FDA notice. Patients and operators looking for licensed pharmacy providers can use the UAE Open Healthcare Directory, which lists 3,898 pharmacy providers and more than 12,390 licensed healthcare providers across the UAE.